By studying individual cardiac cells from heart failure patients, researchers have identified molecular signatures that point to biological mechanisms of disease.
Broad researchers are contributing to Massachusetts’s COVID-19 diagnostic testing, developing new diagnostic technologies and data analysis tools, and generating new biological insights.
The Precision Cardiology Laboratory (PCL) of the Broad Institute and Bayer will focus on using innovative technologies to better understand cardiovascular disease and pursue new drug targets.